SalesAt the end of the day sales will determine whether Ceapro succeeds or fails. I stay focused on that. All of this effort has to translate into increased sales or you are wasting time. Ceapro and the non-Prophet have been very good at the game of distraction, but as is apparent by current valuations, investors arent buying it.
In the OBG instance, impact of OBG on cholesterol is well publicized, nothing groundbreaking here. I am pretty sure Ceapro could already have marketed a pill for "borderline" cholesterol readings where the MD / patient dont want to prescribe / take statins. At the end of the day they will have to have the ability to market a product and compete against other brands anyways so why study? Competitors will use that study data to market their products. Differentiation has to come from the process and purity of compound, always market concerns.
Plans to build mean nothing. So if you announce you are planning to build a plant.....begs the question why? Follow up with the statement that we have increased volume commitments for x and need to increase capacity. That gets shareholders excited.
ACTION = SALES
Interesting data on YBG but the market yawns. Why....because no action, just data. Avenanthramide market commercially exclusive to Ceapro....who cares, no action. Co-enzyme Q10-Beta glucan ready to go.....nothing.
So far Ceapro has shown that they are good at wasting time.and have no desire to roll up their sleeves and take it to the market. They dont seem to recognize an issue or take action to counter measure it. Ceapro stock languishes because of this culture. This has nothing to do with a quick buck investor mindset, everything to do about Ceapro.
To add a humorous analogy.... Give these guys a truck of ice cold bottled water in the middle of the Sahara desert and they would conduct taste testing trials ..... rather than sell it.